Keros Therapeutics (KROS) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 3, 2026, at 11:00 A.M. ET, to be held virtually.

• Proxy materials, including the Notice, Proxy Statement, and Annual Report, are available online for review and voting.

• Stockholders can request paper or email copies of proxy materials at no charge before May 26, 2026.

Voting matters and shareholder proposals

• Election of two Class III director nominees, Jean-Jacques Bienaimé and Charles Newton, to serve until the 2029 Annual Meeting.

• Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory vote to approve executive compensation as disclosed in the Proxy Statement.

• Board recommends voting "FOR" all nominees and proposals.

Board of directors and corporate governance

• Board of Directors' Audit Committee selected Deloitte & Touche LLP as the external auditor for 2026.

• Two director nominees are up for election to serve five-year terms.